A citation-based method for searching scientific literature

Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
Times Cited: 55







List of co-cited articles
662 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future.
Patrick Rossignol, Matthieu Legrand, Mikhail Kosiborod, Steven M Hollenberg, W Frank Peacock, Michael Emmett, Murray Epstein, Csaba P Kovesdy, Mehmet Birhan Yilmaz, Wendy Gattis Stough,[...]. Pharmacol Res 2016
53
1

Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension.
Laurence Bodineau, Alain Frugière, Yannick Marc, Nicolas Inguimbert, Céline Fassot, Fabrice Balavoine, Bernard Roques, Catherine Llorens-Cortes. Hypertension 2008
66
1

Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction.
Michael R Zile, Robert C Bourge, Margaret M Redfield, Duo Zhou, Catalin F Baicu, William C Little. JACC Heart Fail 2014
52
1

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Luis M Ruilope, Rajiv Agarwal, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Christina Nowack, Peter Kolkhof, Amer Joseph, Nicole Mentenich, Bertram Pitt. Am J Nephrol 2019
39
2


A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
Shigehiro Katayama, Daishiro Yamada, Mikihiro Nakayama, Takashi Yamada, Masafumi Myoishi, Masaharu Kato, Christina Nowack, Peter Kolkhof, Yoshimitsu Yamasaki. J Diabetes Complications 2017
33
3

The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
Clare Arnott, Yuli Huang, Brendon L Neuen, Gian Luca Di Tanna, Christopher P Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic,[...]. Diabetes Obes Metab 2020
4
25


Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
Zien Zhou, Richard I Lindley, Karin Rådholm, Bronwyn Jenkins, John Watson, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Wayne Shaw,[...]. Stroke 2019
23
4





Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. J Pharmacol Sci 2016
46
2

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
16
6

Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS.
Song-Tao Dong, Hui-Min Niu, Yin Wu, Jia-Lei Jiang, Ying Li, Kun-Yu Jiang, Xin Wang, Mao-Fan Zhang, Ming-Feng Han, Sheng-Nan Meng. Molecules 2018
6
16

Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
Wing Chow, Gavin Miyasato, Fotios K Kokkotos, Robert A Bailey, Erin K Buysman, Henry J Henk. Clin Ther 2016
5
20

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
Beatriz Fernandez-Fernandez, Raul Fernandez-Prado, Jose Luis Górriz, Alberto Martinez-Castelao, Juan F Navarro-González, Esteban Porrini, María José Soler, Alberto Ortiz. Clin Kidney J 2019
21
4

SGLT1 inhibition: Pros and cons.
Vasilis Tsimihodimos, Sebastien Filippas-Ntekouan, Moses Elisaf. Eur J Pharmacol 2018
12
8


Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Rao N V S Mamidi, Filip Cuyckens, Jie Chen, Ellen Scheers, Dennis Kalamaridis, Ronghui Lin, Jose Silva, Sue Sha, David C Evans, Michael F Kelley,[...]. Drug Metab Dispos 2014
36
2

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Mikhail Kosiborod, Kåre I Birkeland, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Marit E Jørgensen, Eric T Wittbrodt,[...]. Diabetes Obes Metab 2018
45
2

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris,[...]. Circulation 2019
89
1

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Matthew D Culham, Jennifer B Rose,[...]. Diabetes Obes Metab 2019
5
20

Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review.
Thomas R Einarson, Annabel Acs, Craig Ludwig, Ulrik H Panton. Value Health 2018
56
1


Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Sruthi Adimadhyam, Todd A Lee, Gregory S Calip, Daphne E Smith Marsh, Brian T Layden, Glen T Schumock. Diabetes Obes Metab 2018
28
3

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study.
Juan J Gorgojo-Martínez, Manuel A Gargallo-Fernández, Alba Galdón Sanz-Pastor, Teresa Antón-Bravo, Miguel Brito-Sanfiel, Jaime Wong-Cruz. J Clin Med 2020
1
100

Canagliflozin: A Review in Type 2 Diabetes.
Emma D Deeks, André J Scheen. Drugs 2017
17
5

Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Patrick Lefebvre, Dominic Pilon, Marie-Noëlle Robitaille, Marie-Hélène Lafeuille, Wing Chow, Michael Pfeifer, Mei Sheng Duh. Curr Med Res Opin 2016
16
6

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, James Baldassarre, George Bakris, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J L Heerspink,[...]. Circulation 2020
32
3

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
1

CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Jennifer B Rose, Delna Sorabji,[...]. Can J Diabetes 2019
3
33

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk.
Anastasia Erythropoulou-Kaltsidou, Georgios Polychronopoulos, Konstantinos Tziomalos. Diabetes Ther 2020
7
14

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
Jessica W Skelley, Brooke S Carter, Megan Z Roberts. Vasc Health Risk Manag 2018
4
25

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
63
1

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
Toshiaki Ohkuma, Luc Van Gaal, Wayne Shaw, Kenneth W Mahaffey, Dick de Zeeuw, David R Matthews, Vlado Perkovic, Bruce Neal. Diabetes Obes Metab 2020
6
16

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
V Sahasrabudhe, S G Terra, A Hickman, D Saur, H Shi, M O'Gorman, Z Zhou, D L Cutler. J Clin Pharmacol 2017
28
3

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
K M Prasanna Kumar, Sujoy Ghosh, William Canovatchel, Nishant Garodia, Sujith Rajashekar. Indian J Endocrinol Metab 2017
7
14

HbA1c Outcomes in Patients Treated With Canagliflozin Versus Sitagliptin in US Health Plans.
Sarah Thayer, Richard Aguilar, Stephanie Korrer, Wing Chow. Clin Ther 2017
4
25

Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.
Damayanthi Devineni, Joseph Murphy, Shean-Sheng Wang, Hans Stieltjes, Paul Rothenberg, Ellen Scheers, Rao N V S Mamidi. Clin Pharmacol Drug Dev 2015
17
5

SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Ronald M Goldenberg, Lori D Berard, Alice Y Y Cheng, Jeremy D Gilbert, Subodh Verma, Vincent C Woo, Jean-François Yale. Clin Ther 2016
96
1

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Kamel Mohammedi, Mark Woodward, Michel Marre, Stephen Colagiuri, Mark Cooper, Stephen Harrap, Giuseppe Mancia, Neil Poulter, Bryan Williams, Sophia Zoungas,[...]. Cardiovasc Diabetol 2017
32
3

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people.
Anoop Dinesh Shah, Claudia Langenberg, Eleni Rapsomaniki, Spiros Denaxas, Mar Pujades-Rodriguez, Chris P Gale, John Deanfield, Liam Smeeth, Adam Timmis, Harry Hemingway. Lancet Diabetes Endocrinol 2015
441
1


Canagliflozin review - safety and efficacy profile in patients with T2DM.
Haroon Jakher, Tara I Chang, Marilyn Tan, Kenneth W Mahaffey. Diabetes Metab Syndr Obes 2019
14
7


Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology.
Richard M Cubbon, Brook Adams, Adil Rajwani, Ben N Mercer, Peysh A Patel, Guy Gherardi, Christopher P Gale, Phillip D Batin, Ramzi Ajjan, Lorraine Kearney,[...]. Diab Vasc Dis Res 2013
101
1

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Carol H Wysham, Patrick Lefebvre, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Wing Chow, Michael Pfeifer, Mei Sheng Duh. BMC Endocr Disord 2017
4
25

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
M B Rehman, B V Tudrej, J Soustre, M Buisson, P Archambault, D Pouchain, H Vaillant-Roussel, F Gueyffier, J-L Faillie, M-C Perault-Pochat,[...]. Diabetes Metab 2017
58
1


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.